Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (February 2017)
25 slides from Moleculin Biotech's investor presentation, Feb 28, 2017
Slide 1: Moleculin Biotech - February 28, 2017
NASDAQ : MBRX February 28, 2017
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward - looking statements . The words “believ
Slide 3: Recent Offering
Recent Offering Issuer Moleculin Biotech, Inc. Security Unit consisting of one share of common stock and 1) an “A” five year w arrant to purchase 0.50 shares at $1.50 per share; 2) a “B” 90 day warrant to purchase 1.00 share of common stock at $1.35 per share; and 3) Upon exercise of the “B” warrant
Slide 4: Robust pipeline with blockbuster potential
4 Robust pipeline 3 distinctly different technologies, all with blockbuster potential World - leading collaboration MD Anderson Cancer Center Breakthrough disruptive technologies Annamycin for AML: little to no cardiotoxicity , avoids MDR1 WP1066: STAT3 inhibitor that also stimulates immune response
Slide 5: Experienced Management Team
Experienced Management Team Selected Prior Experience Walter Klemp Chairman & CEO Don Picker, PhD President & COO Jonathan P. Foster. CPA, CGMA EVP & CFO Robert Shepard, MD, FACP Chief Medical Officer 5 #1
Slide 6: Science Advisory Board Members
Selected Prior Experiene Waldemar Priebe, PhD Madeleine Duvic, MD John Paul Waymack, MD, SCD Sandra Silberman, MD, PhD Science Advisory Board Members 6
Slide 7: Development Pipeline
Development Pipeline 7 Discovery (Finding potential new drugs) Pre - Clinical Development (Laboratory Testing) IND Filing (Investigational New Drug; FDA Filing) Phase I/II (Human safety & proof of concept) Approval Trial (Phase IIb or III as required) Adult AML WP1066 (Glioblastoma, metastatic melan
Slide 8: Value Inflection Points
Value Inflection Points Points we consider to be key development milestones that may influence big pharma’s decision to license or acquire: • Annamycin – generation of Phase I/II data consistent with the clinical trials already completed • WP1066 and WP1122 – Proof of concept (showing activity again
Slide 9: Development Strategy
Development Strategy 9 • Orphan Drug targets with high revenue potential • Focus on game - changing breakthroughs • Collaborate closely with MD Anderson Cancer Center • Minimize cash burn through virtual structure • Worldwide exclusive licenses and regulatory exclusivity create proprietary positioni
Slide 10: Industry Opportunity
Industry Opportunity 10 • Orphan Drug sales represented approximately $29 billion in revenue in 2013 • There are no approved second - line therapies for AML • CPXX sold for $1.5 billion based on improving OS by 3.5 months, yet still leaves most AML patients without hope • Similar opportunities exist
Slide 11: MD Anderson Cancer Center collaboration
Most of our technologies were developed at MD Anderson Cancer Center, the world’s largest cancer research facility centered within the world’s largest medical center With over 1 , 500 cancer researchers, our sponsored research has been supported by truly state of the art resources 11
Slide 12: Delivering Solutions
Delivering Solutions 12
Slide 13: Annamycin Critical Advantages over Leading Drug
Annamycin Critical Advantages over Leading Drug Leading drugs are cardiotoxic and lose efficacy due to multidrug resistance Annamycin has shown little to no cardiotoxicity , avoids multidrug resistance, has been shown to be more potent in AML cell lines and has shown activity in patients who failed
Slide 14: Moleculin
Ss Moleculin “4
Slide 15: Annamycin Delivers Remarkable Performance
Annamycin Delivers Remarkable Performance In a proof - of - concept Phase I/II clinical trial, Annamycin was given to patients who had failed an average of five previous induction therapy attempts 37% of those patients cleared enough of their leukemic cells to qualify for a bone marrow transplant We
Slide 16: Induction therapy and bone marrow transplant
20% 80% Induction Therapy (Qualify for BMT) Success Failure 80 % 20 % BMT (Results in Cure) Leukemia is a cancer of the white blood cells and the acute forms of leukemia can manifest quickly and leave patients with limited treatment options The only viable option for acute leukemia patients is a bon
Slide 17: Annamycin: what is possible with a higher MTD
17 Annamycin (based on last trial) What is possible if we get to patients sooner with a higher MTD?
Slide 18: WP1066 Portfolio Overview
WP1066 Portfolio Overview Based On Natural Compound Built from chemical backbone of bee pollen compound Unique Dual Action First drug to both directly inhibit tumor signaling while also stimulating patient immune response Activity Against Hardest - to - Treat Cancers Pre - clinical testing shows hig
Slide 19: Proposed MOA of WP1066
Proposed MOA of WP1066: Deubiquitinase - Mediated Control of p - STAT3 19 Proteasome Proteasomal Degradation p - STAT3, an activated form of STAT3 Ubiquitinated STAT3 Activated STAT3 (p - STAT3) relies on deubiquitinating enzymes (DUBs) to reverse ubiquitination and decrease proteasomal hydrolysis W
Slide 20: WP1122 Portfolio Overview
WP1122 Portfolio Overview Tumor cell Normal cell Addicted to Sugar A brain tumor requires as much as 18 to 37 times as much glucose to survive as a healthy brain cell Starving a Tumor to Death This eventually led to the theory that, if we feed tumor cells a glucose decoy (one that can’t convert into
Slide 21: WP1122 is Effective In Vivo against Gliomas
WP1122 is Effective In Vivo against Gliomas 21 Orthotopic Glioblastoma Model in Mice WP1122 used alone has at least the same or greater activity than temozolomide ( Temodar ® ), a current standard of care in patients diagnosed with glioblastoma 0 2 4 6 8 10 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Slide 22: Financial Overview
Financial Overview 22
Slide 23: Financial Statement Summary
Financial Statement Summary The above unaudited financial information should be read with the notes, the financial statements of Moleculin and the notes the reto which are included in the Form 10 - Q for the quarter ended September 30, 2016 . 23 For the Nine Months Ended September 30, 2016 From July
Slide 24: Upcoming Potential Milestones
Upcoming Potential Milestones Annamycin • Approval of an Investigative New Drug application by the FDA (first half of 2017) • Receipt of Orphan Drug Status (first half of 2017) • Announcement of the beginning of Phase I/II clinical trials (first half of 2017) • Establishment of the MTD (2017) • Resu
Slide 25: Robust pipeline distinctly different technologies
25 Robust pipeline 3 distinctly different technologies, all with blockbuster potential World - leading collaboration MD Anderson Cancer Center Breakthrough disruptive technologies Annamycin for AML: little to no carditoxicity , avoids MDR1 WP1066: STAT3 inhibitor that also stimulates immune response
Moleculin Biotech — Investor Presentation (February 2017) on 6ix